Symberix

Small molecules that act upon human microbiome

SBX-201 RD IBD, lower GI disorders; SBX-301 RD intestinal toxicities from cancer drugs

Symberix is developing microbiome-targeted small molecule drugs to treat gastrointestinal diseases. Gut dysbiosis occurs when there is an imbalance of good versus bad microbes in the gut and can contribute to a variety of human diseases. Symberix is identifying small molecules that can effectively inhibit the harmful activities of gut bacteria without killing beneficial microbes. Through this approach, Symberix has created a library of novel, potent bacteria-selective beta-glucuronidase (GUS) inhibitors. GUS activity in the gut microbiota is linked with intestinal inflammation and Symberix is advancing their lead candidate, SBX-101 to provide treatment options for patients with inflammatory bowel disease.